A recent analysis compares BioNTech and Moderna, highlighting their market positions.
The analysis titled 'Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?' has sparked interest among investors in the mRNA sector. BioNTech SE's stock closed at US$96.28, reflecting a 1-day increase of 0.76%. However, over the past week, the stock has decreased by 1.45%, and it has seen a decline of 5.90% over the past month. Year-to-date, BioNTech's stock has gained 0.98%.
Investor takeaway: Investors should consider the comparative analysis as part of their research on mRNA stocks.
Advertisement
BioNTech SE
BNTX.US
BNTX.US
BioNTech SE
WealthAwesomeMarket cap
$24.53B
52W high
$124.00
52W low
$79.52
1W change
-1.45%
Beta
1.25
Analyst Price Targets
Based on 20 analysts covering BNTX · as of Oct 6, 2026
Wall Street analysts forecast BNTX stock price to rise 18.6% over the next 12 months.
Consensus
Buy4.30 / 5.00
Avg. Target
C$115.78
+18.6% Upside
Previously C$116.14 on Oct 5, 2026
Current Price
C$97.64
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BNTX's historical volatility
30-Day Vol
37.7%
Annualized
90-Day Vol
47.1%
Annualized
Trend (90d)
+27.3%
Annualized drift
90d Mean
C$107.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$100.87 | C$88.56 – C$114.88 |
| 60 trading days | C$104.20 | C$86.69 – C$125.26 |
| 90 trading days | C$107.65 | C$85.93 – C$134.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
BioNTech's Stock Performance: +0.76% on Latest Trading Day
BioNTech closed at US$96.28, with a volume of 471,928 shares traded, significantly above its 20-day average.
Bull case
Analysts believe BioNTech has growth potential, with an average target price of US$115.78. This suggests a possible upside of 20.3% from its current price.
Bear case
On the downside, BioNTech has a negative profit margin of -63.6% and has struggled with stock performance over the past month, raising concerns about its financial health.
BioNTech's Stock Performance on Recent Analysis
Advertisement
BioNTech SE's stock increased by 0.76% on the latest trading day, closing at US$96.28. This uptick comes after a challenging week where the stock saw a decline of 1.45%. The trading volume was 471,928 shares, which is 1.72 times its 20-day average of 835,565 shares. BioNTech's stock is currently positioned at 38% of its 52-week range, which spans from US$79.52 to US$124.00, suggesting a potential for recovery as it moves within this range.
Financial Metrics and Market Sentiment
Despite the recent uptick in stock price, BioNTech has a negative profit margin of -63.6% and a return on equity (ROE) of -9.3%. The stock's performance over the last month has seen a decline of 5.90%, raising questions about its financial sustainability. Analysts have set an average target price of US$115.78 for the stock, implying a potential increase of 20.3% from its current valuation. Additionally, BioNTech's last close is below both its 50-day moving average of US$98.52 and its 200-day moving average of US$97.70.
Looking Ahead: Market Dynamics in mRNA Sector
Investors will be watching how BioNTech responds to the competitive dynamics in the mRNA sector, particularly in light of the analysis comparing it to Moderna. The insights reveal that ongoing developments in personalized mRNA cancer vaccines and other innovations could influence stock performance. As the healthcare sector continues to evolve, keeping track of BioNTech's strategic initiatives will be crucial for understanding its market position. With a market cap of approximately US$24.53 billion, BioNTech remains a significant player in the healthcare landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
